NETest and Gastro-Entero-Pancreatic Neuroendocrine Tumors: Still Far from Routine Clinical Application? A Systematic...

Area of Science:

• Oncology
• Biomarker Discovery
• Genomics

Background:

• Gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) are a heterogeneous group with variable clinical behavior.
• The NETest, utilizing real-time PCR and deep learning, identifies neuroendocrine genotypes.
• NETest is not yet standard clinical practice despite promising GEP-NET applications.

Purpose of the Study:

• To systematically review the diagnostic and prognostic utility of the NETest in GEP-NETs.
• To summarize evidence on NETest's accuracy and reliability for GEP-NET patient stratification.

Main Methods:

• Systematic review of studies evaluating NETest for GEP-NET diagnosis and prognosis.
• Analysis of diagnostic accuracy, specificity, and prognostic correlations.

Main Results:

• NETest demonstrated over 90% accuracy for GEP-NET diagnosis, irrespective of stage or grade.
• Some studies noted low specificity due to interference from other GI malignancies.
• NETest correlated with residual disease detection and improved prediction of progression-free survival (PFS) and overall survival (OS).

Conclusions:

• The NETest shows robust diagnostic and prognostic value for GEP-NETs across multiple studies.
• Further prospective validation in larger GEP-NET cohorts is recommended.
• The NETest holds potential for improving GEP-NET diagnosis, management, and follow-up.